EFM
GLUE icon

E Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

E Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Sell
8,285
-4,866
-37% -$91.9K ﹤0.01% 456
2026
Q1 		$216K Buy
+13,151
New +$251K 0.01% 439

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

E Fund Management's GLUE Position: Q2 2026 in Review

E Fund Management reduced its Monte Rosa Therapeutics (GLUE) stake by 37% in Q2 2026, selling an estimated $91.9K and leaving 8,285 shares worth $200K. The position accounts for ﹤0.01% of the portfolio, ranked #456.

E Fund Management first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. The position peaked at $216K in Q1 2026. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • E Fund Management held 8,285 shares of Monte Rosa Therapeutics worth $200K as of Q2 2026.
  • E Fund Management sold 4,866 Monte Rosa Therapeutics shares in Q2 2026, an estimated $91.9K.
  • Monte Rosa Therapeutics made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #456 holding.
  • E Fund Management first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • E Fund Management's Monte Rosa Therapeutics position peaked at $216K in Q1 2026.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.